2025-521910-24-00Not yet recruitingPhase 4
Effects of CLADribine tablets on the Immune Synapse, in Relapsing Multiple Sclerosis (RMS) patients_CLADIS.
Source: EU CTIS (euclinicaltrials.eu) · Last updated 3 Jul 2026
Brief summary (registry, in English)
The primary endpoint is to assess changes in the immune synapse molecules in naive MS patients treated with cladribine tablets compared to healthy volunteers, at 12-months of treatment.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 19 Jan 2026
- Start date
- 20 Feb 2026
- Lead sponsor
- Aristotle University Of Thessaloniki
- Diseases
- Multiple sclerosis
- EU CT number
- 2025-521910-24-00
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 30
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
AI-kivonat: who the study is looking for
Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with relapsing-remitting multiple sclerosis who have never been treated for it and will start cladribine tablets as prescribed by their doctor.
- Age
- 18 to 50 years old
- Sex
- All sexes
- Disease stage
- Relapsing-remitting multiple sclerosis (RRMS), diagnosed with a full workup in the 6 months before joining. No progressive MS.
- Earlier treatment
- Must not have had any other disease-modifying treatment (DMT) for MS before. Cladribine is prescribed by the treating doctor as in the approved MAVENCLAD product information in Greece.
Main reasons for not taking part
- Any reason in the product information that rules out cladribine tablets
- Other neurological disease
- History of alcohol or drug abuse that could interfere with taking part
- Taking part in another investigational study at the same time
- MS diagnosed more than 6 months before joining
Read by machine on 9 Nov 2026.
Who cannot take part
Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Concurrent participation in an investigational study in which patient assessment and/or treatment may be dictated by a protocol
- Prior or current use of other DMT
- MS diagnosis >6 months prior to the inclusion to the study
Other illness
- Patients with history of alcohol or drug abuse that could potentially interfere with their participation in the study
Age
- Age <18 or >50
Other
- Contraindications to use of cladribine tablets according to the Summary of Product Characteristics
- Evidence of progressive MS
Who the study is looking for
- Patients with RRMS, age ≥18 and ≤50 years old
- Treatment naive
- Cladribine prescription per the decision of the treating physician and according to the approved MAVENCLAD SmPC in Greece
- Absence of other neurological disease
- Willingness / ability to provide written informed consent
- Full diagnostic workup for MS in the previous 6 months prior to the inclusion to the study
Age in the registry: 18 years to 64 years · Sex: All · Accepts healthy volunteers
Sites (2)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University General Hospital of Thessaloniki - AHEPA | Thessaloniki | Greece | Not yet recruiting |
| Papageorgiou Hospital | Thessaloniki | Greece | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.